soul trial oral semaglutide cardiovascular outcomes 2024 results mace reduction Canadian Perspectives 2025 Whiteboard on the Oral Semaglutide Approved to Reduce

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

This overestimate will assist in contextualizing a worst-case scenario of infant systemic exposure to semaglutide via milk in the setting of maternal subcutaneous use

Phase 2 trial of baxdrostat for treatment-resistant hypertension

Chen M, Ji C, Yang Q, Gao S, Peng Y, Li Z, et al

Their paper, The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review, was published in the journal Clinical Endocrinology

Some employer-sponsored or marketplace policies may offer partial or full coverage for semaglutide prescribed for weight management, especially if the insurer recognizes obesity as a medical condition